RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases

BENGALURU, India, Dec. 10, 2024 RenaissThera Private Limited, a pioneering Bengaluru-based biotechnology company, has successfully closed its seed funding round backed by angel investors. RenaissThera is revolutionizing the fight against cardio-metabolic diseases like diabetes and obesity through its AI-powered Innovation Platform, leveraging Generative AI and machine learning to rapidly identify and optimize small molecules for targeted therapies. Mr. Sudhir Nagarajan, Managing Director, said, “We thank all the investors in this round for their support and belief in our team and the promise of RenaissThera in delivering innovative medicines.” With the successful close of its seed funding round, CEO Dr. Ramkesh Meena stated, “This milestone enables us to scale up and validate our early-stage pipeline in pre-clinical proof-of-concept studies and get ready for IND filing next year, propelling us closer to delivering life-changing, affordable therapies that address critical gaps in care.” This innovative approach combines scientific rigor and efficiency to reduce development timelines and costs while improving patient outcomes worldwide. About RenaissThera RenaissThera, based in Bengaluru, India, is a biotechnology company dedicated to developing affordable, novel small-molecule targeted therapies leveraging AI platforms.